Paper Details

  1. Home
  2. Paper Details

Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II.

Author: EnghelbergMoises, KaifeeSyeda

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This is the first case report of neratinib maculopathy, a rare side effect of the tyrosine kinase inhibitor (TKI) neratinib used for breast cancer treatment. The patient exhibited macular toxicity similar to macular telangiectasia type II. This case emphasizes the importance of baseline retinal examinations in patients undergoing chemotherapy, particularly when using TKIs or other drugs with known retinal side effects.
Paper Details　
Original Abstract of the Article :
The purpose of this case report is to present the first case of neratinib maculopathy. We describe the initial presentation, baseline characteristics, imaging findings, and outcomes. The case report is accompanied by a thorough literature review including possible mechanisms of tyrosine kinase inhib...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941022/

データ提供：米国国立医学図書館（NLM）

Neratinib Maculopathy: A Hidden Oasis in the Desert of Ocular Toxicity

The desert of ocular toxicity is a vast and challenging terrain, with researchers constantly searching for new oases of knowledge and effective treatments. This study delves into the potential ocular toxicity of neratinib, a tyrosine kinase inhibitor (TKI) commonly used in the treatment of breast cancer. The authors present a case report, a detailed account like a caravan's journal, of a patient who developed suspected neratinib maculopathy, a rare and potentially overlooked side effect.

Neratinib Maculopathy: A Potential Oasis in the Desert of Ocular Toxicity

The case report highlights the need for vigilance in monitoring patients treated with neratinib for potential ocular side effects. This discovery is like finding a hidden oasis in the desert, offering a potential source of warning for healthcare providers. The authors recommend baseline retinal examinations for patients undergoing chemotherapy with neratinib to detect potential maculopathy early.

Navigating the Desert of Ocular Toxicity: A Journey of Careful Observation

The case report emphasizes the importance of careful observation and thorough assessment of potential ocular side effects in patients undergoing chemotherapy. It's a reminder that navigating the desert of ocular toxicity requires a commitment to patient safety and a dedication to seeking knowledge.

Dr.Camel's Conclusion

The desert of ocular toxicity is a challenging landscape, requiring vigilance, knowledge, and a commitment to patient safety. This case report provides valuable insights into the potential ocular toxicity of neratinib, reminding us that we must continue to explore this terrain with a spirit of curiosity and a dedication to improving patient care.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-02-26
Further Info :

Pubmed ID

36824546

DOI: Digital Object Identifier

PMC9941022

Related Literature

Article Analysis
・Side Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.